Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
36.73
USD
+0.03 (+0.08%)
Official Closing Price
Updated: 7:59 PM EST, Jan 19, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Pfizer
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Pfizer Outlines Five-Point Plan to Battle COVID-19
March 13, 2020
Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
From
Business Wire News Releases
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
March 13, 2020
Not intended for UK-based media
From
PR Newswire
Thinking about trading options or stock in Costco, Walt Disney, Facebook, Pfizer, or UnitedHealth?
March 12, 2020
InvestorsObserver issues critical PriceWatch Alerts for COST, DIS, FB, PFE, and UNH.
From
PR Newswire
New GeoMap Tools Get Patient Recruitment Back on Track During the COVID-19 Outbreak
March 09, 2020
From
ACN Newswire
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen
March 09, 2020
ViiV HC presents positive long-term phase III study data demonstrating efficacy and safety of cabotegravir and rilpivirine in adults living with HIV-1
From
Business Wire News Releases
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once
March 09, 2020
ViiV HC presents positive phase III study showing every-two-month regimen of cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
From
Business Wire News Releases
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
March 09, 2020
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
From
Business Wire News Releases
Thinking about trading options or stock in Apple, Bank of America, Pfizer, Paypal, or Uber?
March 06, 2020
InvestorsObserver issues critical PriceWatch Alerts for AAPL, BAC, PFE, PYPL, and UBER.
From
PR Newswire
Global Market For Cancer Therapies Could Exceed US$220 Billion By 2025
March 04, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Market for Cancer Therapies Could Exceed US$220 Billion by 2025
March 04, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Susan Hockfield Elected to Pfizer’s Board of Directors
March 04, 2020
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and Compliance...
From
Business Wire News Releases
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV
March 02, 2020
ViiV HC initiates study with USC to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV
From
Business Wire News Releases
U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
March 02, 2020
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5...
From
PR Newswire
James Quincey Elected to Pfizer’s Board of Directors
February 27, 2020
Pfizer Inc. (NYSE: PFE) today announced the election of James Quincey to its Board of Directors, effective immediately. Mr. Quincey, age 55, was also appointed to the Compensation Committee and the...
From
Business Wire News Releases
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
February 27, 2020
- Pfizer's Upjohn Division CFO Sanjeev Narula selected for leadership role at combined company -
From
PR Newswire
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
February 27, 2020
Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) today announced that Sanjeev Narula, current chief financial officer (CFO) of Upjohn, a division of Pfizer, has been named incoming CFO of Viatris, the...
From
Business Wire News Releases
Mylan and Pfizer Finalize Appointments to Viatris Board of Directors
February 27, 2020
13 Inaugural Directors Bring Wide-Ranging Experience, Expertise and a Focus on Driving Shareholder Value
From
PR Newswire
Mylan and Pfizer Finalize Appointments to Viatris Board of Directors
February 27, 2020
Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced the remaining appointees to the inaugural 13-member Board of Directors for Viatris, the new company that will result from the...
From
Business Wire News Releases
Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first milestone payment related to Asia-Pacific
February 27, 2020
From
GlobeNewswire News Releases
Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer
February 26, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer
February 26, 2020
FN Media Group Presents USA News Group News Commentary
From
PR Newswire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 25, 2020
Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the Cowen and Company 40th...
From
Business Wire News Releases
Thinking about trading options or stock in Bank of America, Deere & Company, Pfizer, Tesla, or UnitedHealth Group?
February 21, 2020
InvestorsObserver issues critical PriceWatch Alerts for BAC, DE, PFE, TSLA, and UNH.
From
PR Newswire
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
February 18, 2020
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin...
From
Business Wire News Releases
Pediatric Brain Tumor Drug Market Is Growing Continuously and Could Reach US$1,659.4 Million by 2023
February 11, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Pediatric Brain Tumor Drug Market is Growing Continuously and Could Reach US$1,659.4 Million by 2023
February 11, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC
February 11, 2020
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3...
From
PR Newswire
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
January 31, 2020
Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing...
From
Business Wire News Releases
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer
January 30, 2020
Melanie Ivarsson, Ph.D. joins Moderna as Chief Development Officer.
From
Business Wire News Releases
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
January 28, 2020
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2019 and provided 2020 financial guidance.
From
Business Wire News Releases
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.